Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2001

View Archived Issues

Organogenesis and Biomet establish product development agreement

Immune Response updates Remune development program

OraPharma commences phase I trial of OC-1012 for mucositis prevention

SBIR grant received by Acorda for spinal cord injury regeneration research

MediGene signs agreement with Memorial Sloan-Kettering for HSV in cancer treatment

GE Medical Systems and GSK collaborate on molecular imaging technologies

Single and multiple oral doses of SPP-100 provide sustained RAS inhibition in humans

RSD-1235 terminates atrial fibrillation in dogs

ACS news: preparation of ABT-839 for toxicology and clinical studies

MMP-1-sparing matrix metalloproteinase inhibitors possessing antiangiogenic/antitumor properties

Preclinical and phase I/II study findings on VEGF165 gene therapy reported at ESC congress

Medivir and Chiron establish collaboration for novel HCV drugs

Efficacy of antisense therapy with AVI-4126 demonstrated in preclinical testing

New DIC therapeutic scheduled for filing soon by Japanese company

RegeneRx and UT Southwestern establish research agreement for TB4

Role of proteasome and proteasome inhibitors in vascular restenosis

Novel therapeutic approach to autoimmune diseases identified by ZymoGenetics and Serono

DuPont presents data on vitronectin receptor antagonist-based tumor imaging agents

FDA issues complete response letter for FluMist BLA

Class III/IV/Ib antiarrhythmic properties also seen for EGIS-7229 in human myocardium

FDA grants orphan drug status for new Genasense indications

Preclinical studies continue to define spectrum, susceptibility criteria of GAR-936

Karo Bio and AHP to develop new atherosclerosis drug

Novel treatments for rheumatoid arthritis and other autoimmune diseases presented by Dainippon

iGluR5-selective glutamate receptor antagonists useful for migraine Rx

Potential analgesic agents claimed by AstraZeneca in recent patents

Antiviral quinolones under study at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 17, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...